Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer.

Yee NS, Zhou W, Chun SG, Liang IC, Yee RK.

Biol Open. 2012 Apr 15;1(4):295-307. doi: 10.1242/bio.2012539. Epub 2012 Feb 10.

2.

Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.

Chun SG, Zhou W, Yee NS.

Cancer Biol Ther. 2009 Jul;8(14):1328-39. Epub 2009 Jul 6.

PMID:
19421011
3.

Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.

Zhou W, Liang IC, Yee NS.

Cancer Biol Ther. 2011 Apr 1;11(7):659-70. Epub 2011 Apr 1.

4.

Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.

Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y.

PLoS One. 2012;7(12):e52095. doi: 10.1371/journal.pone.0052095. Epub 2012 Dec 14.

5.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.

Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP.

Int J Cancer. 2007 Aug 1;121(3):656-65.

7.

Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.

Zhu Z, Jiang W, McGinley JN, Thompson HJ.

Cancer Prev Res (Phila). 2013 Apr;6(4):290-8. doi: 10.1158/1940-6207.CAPR-12-0449-T. Epub 2013 Jan 30.

9.
10.
11.

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.

J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.

PMID:
26314218
12.

Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.

Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y.

Carcinogenesis. 2013 Jun;34(6):1196-207. doi: 10.1093/carcin/bgt033. Epub 2013 Jan 25.

13.

Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells.

Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A, Palmieri M.

Mol Carcinog. 2003 Oct;38(2):59-69.

PMID:
14502645
14.

Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors.

Haumaitre C, Lenoir O, Scharfmann R.

Mol Cell Biol. 2008 Oct;28(20):6373-83. doi: 10.1128/MCB.00413-08. Epub 2008 Aug 18.

15.

Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers.

Chun SG, Park H, Pandita RK, Horikoshi N, Pandita TK, Schwartz DL, Yordy JS.

Am J Cancer Res. 2015 Mar 15;5(4):1337-52. eCollection 2015.

16.

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9.

17.

Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.

Sato A, Asano T, Ito K, Sumitomo M, Asano T.

BJU Int. 2012 Apr;109(8):1258-68. doi: 10.1111/j.1464-410X.2011.10533.x. Epub 2011 Sep 2.

18.

Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P.

Am J Transl Res. 2009;1(1):62-71. Epub 2009 Jan 1.

19.

In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).

Hendricks JA, Keliher EJ, Marinelli B, Reiner T, Weissleder R, Mazitschek R.

J Med Chem. 2011 Aug 11;54(15):5576-82. doi: 10.1021/jm200620f. Epub 2011 Jul 18.

20.

Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3.

Malinen M, Saramäki A, Ropponen A, Degenhardt T, Väisänen S, Carlberg C.

Nucleic Acids Res. 2008 Jan;36(1):121-32. Epub 2007 Nov 13.

Supplemental Content

Support Center